December 24, 2014 | The Food & Drug Administration in the United States has approved Teva Pharmaceutical Company‘s GRANIX injection solution for sale and distribution in the US. GRANIX’s system works to hasten the flow of white blood cells and to strengthen the immune system, especially during chemotherapeutic treatments. GRANIX has been present on the American market since November 2013, but is currently only available for distribution at hospitals and by doctors. Now Teva plans to release a new version of the GRANIX injection device that can be self-dosed and injected by patients and medical service providers. Teva is Israel’s largest pharmaceutical company, founded in 1901 and managed by CEO and president Erez Vigodman.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments